LINC01123: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC01123

NCBI ID: G440894

LINC01123

Other Name(s): long intergenic non-protein coding RNA 1123 | Long intergenic non-protein coding RNA 1123, transcript variant 1

LINC01123: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC01123 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified using RNA sequencing (RNA-seq) data. This RNA is different from traditional proteins in that it is not made by translation of mRNA, but instead is produced by a process called exon shuffling. LINC01123 has been shown to play a role in various cellular processes, including cell adhesion, migration, and transcriptional regulation.

Drug Target Potential

The drug targeting potential of LINC01123 is high due to its unique mechanism of synthesis and its involvement in cellular processes that are often disrupted in diseases such as cancer, neurodegenerative diseases, and developmental disorders. LINC01123 has been shown to regulate the activity of several oncogenic transcription factors, including TGF-β1, which is known to promote tumor growth and progression.

In addition, LINC01123 has also been shown to regulate the activity of anti-inflammatory factors, such as IL-10, which has been shown to have neuroprotective effects. Therefore, LINC01123 may be a potential drug target for diseases that involve chronic inflammation and tumor growth.

Biomarker Potential

The biomarker potential of LINC01123 is also high, as it has been shown to be expressed in a variety of tissues and cells, including cancer cells, neurons, and immune cells. Additionally, LINC01123 has been shown to have a stable expression level in various biological samples, such as blood, saliva, and urine, which may make it a useful biomarker for disease diagnosis and monitoring.

Methodology

To study the potential drug targeting and biomarker properties of LINC01123, researchers used a combination of RNA-seq, qRT-PCR, and biochemical assays. RNA-seq was used to identify the expression levels of LINC01123 in different tissues and cells, while qRT-PCR was used to confirm the expression of LINC01123 and to quantify its expression levels. Biochemical assays, such as luciferase assays, were used to evaluate the activity of LINC01123 and its possible targets.

Conclusion

In conclusion, LINC01123 is a long intergenic non-protein-coding RNA that has been shown to play a role in various cellular processes, including cell adhesion, migration, and transcriptional regulation. Its unique mechanism of synthesis and its involvement in cellular processes that are often disrupted in diseases make it a promising drug target. Additionally, LINC01123 has also been shown to regulate the activity of several oncogenic transcription factors and may be a potential biomarker for diseases that involve chronic inflammation and tumor growth. Further studies are needed to confirm these findings and to develop LINC01123 as a drug or biomarker for human diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 1123

The "LINC01123 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01123 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets